Absci Corp
A biotech company that uses artificial intelligence and synthetic biology to design antibodies and other proteins for new medicines. Founded in 2012 by Sean McClain in Vancouver, Washington, the name "Absci" is short for "antibody science." Its platform pairs generative AI with high-throughput lab testing to help drugmakers develop biologic therapies, and it went public through a SPAC merger in 2021.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Redmile Group, LLC | 13D/AActivist | 4.9% | 7.61M | Apr 14, 2026 |
| Jeremy C. Green | 13D/AActivist | 4.9% | 7.61M | Apr 14, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| Sean McClain | 13G/APassive | 7.2% | 11.00M | Nov 13, 2025 |
| BlackRock, Inc. | 13G/APassive | 6.5% | 8.32M | Jul 16, 2025 |
| Phoenix Venture Partners II, LP | 13G/APassive | 3.7% | 4.75M | May 15, 2025 |
| Phoenix General Partner II LLC | 13G/APassive | 3.7% | 4.75M | May 15, 2025 |
| Alger Associates, Inc. | 13G/APassive | 3.4% | 4.29M | May 15, 2025 |
| ARK Investment Management LLC | 13G/APassive | 8.6% | 10.96M | May 14, 2025 |
| Catherine D. Wood | 13G/APassive | 8.6% | 10.96M | May 14, 2025 |